Pharma Focus Asia

Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville

Wednesday, April 17, 2019

Recro Pharma, Inc., a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that Recro Gainesville LLC, its CDMO division, has amended its existing license and supply agreement with Teva Pharmaceutical to extend the agreement for six years, effective January 1, 2019.

Under the terms of the amended Agreement, Recro Gainesville will continue to supply Teva with Verapamil SR capsules through 2024 and Teva will continue to be Recro Gainesville’s exclusive United States distributor of the product, for which Recro Gainesville is the New Drug Application holder.  The 2019 Teva Agreement provides to Recro Gainesville the same revenue economics as the original agreement, including both manufacturing and profit sharing components.  Prior to this amendment, the license and supply agreement with Teva for Verapamil SR was renewable on a year-to-year basis.

“Teva is the largest generic pharmaceutical company in the world and continues to do a tremendous job as our exclusive marketing partner for Verapamil SR,” said Scott Rizzo, Senior Vice President, General Manager of Recro Gainesville. “The 2019 Teva Agreement both extends our baseline manufacturing business for a substantial period of time and serves as a solid foundation upon which to add new CDMO customers.”

Gerri Henwood, Recro Pharma's President and Chief Executive Officer, commented, “We have maintained a close working partnership with Teva and they have delivered strong product volume through their unparalleled distribution channels.  This amendment underscores the commitment and dedication of our employees in Gainesville to maintain high quality standards and consistently deliver product on time to meet increasing demand. We are delighted Teva will continue to be our exclusive distributor in the United States for the next six years.”

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024